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Pseudo-Hurler polydystrophyMucolipidosis II and III (MLII and MLIII) alpha/beta are rare autosomal recessive lysosomal storage diseases
(LSDs) caused by pathogenic variations in the GNPTAB gene. GNPTAB gene codes for the α and β subunits
of phosphotransferase, the enzyme responsible for synthesis of the mannose-6-phosphate (M6P) marker
that directs lysosomal enzymes to the lysosome.
Objectives: The objective of this study is to identify sequence variations of the GNPTAB gene in Brazilian
patients with MLII and MLIII alpha/beta.
Method: Sequencing of the GNPTAB gene was performed in samples of gDNA extracted from the peripheral
blood of patients with MLII/III diagnosed at a national reference center for LSDs.
Results: Twelve unrelated patients, from several regions of Brazil, were included in this study. Only one was
born of consanguineous parents. All patients were found to carry at least one nonpathogenic variation. Nine
causal sequence variations were found: c.242G>T (p.W81L); c.1123C>T (p.R375X); c.1196C>T (p.S399F);
c.1208T>C (p.I403T); c.1514G>A (p.C505Y); c.1759C>T (p.R587X); c.2808A>G (p.Y937_M972del, novel
mutation); c. 2269_2273delGAAAC (p.E757KfsX2, novel mutation); and c.3503_3504delTC (p.L1168QfsX5).
Both pathogenic variations were identiﬁed in 8 of 12 patients; in four patients, only one pathogenic variation
was identiﬁed. Mutation c.3503_3504delTC, located in exon 19, was the most frequent pathogenic variation
found (n = 11/24 alleles). The deleterious effect of the c.2808A>C mutation on splicing was conﬁrmed by
cDNA analysis.
Discussion/conclusions: Our ﬁndings conﬁrm that the GNPTAB gene presents broad allelic heterogeneity and
suggests that, in Brazilian ML II and III patients, screening for mutations should begin at exon 19 of the
GNPTAB gene. Further analyses will be conducted on patients in whom both pathogenic mutations have
not been found in this study.
© 2013 Elsevier B.V. Open access under the Elsevier OA license.AA, mRNA codon for amino acid glutamine; CAG, mRNA codon for amino acid glutamic acid; cDNA, DNA complementary to
lvimento; CUA, mRNA codon for amino acid leucine; CUG,mRNA codon for amino acid leucine; DBS, dried blood spot; dNTPs,
; ELISA, enzyme-linked immunosorbent assay; FAPERGS, Fundação de Amparo à Pesquisa do estado do Rio Grande do Sul;
Hospital de Clínicas de Porto Alegre; GAGs, glycosaminoglycans; gDNA, genomic deoxyribonucleic acid; GlcNAc-PT,
etyl_1-phosphotransferase; GNPTAB, ofﬁcial symbol for the gene “N-acetylglucosamine-1-phosphate transferase, alpha
gene “N-acetylglucosamine-1-phosphate transferase, gamma subunit”; HCPA, Hospital de Clínicas de Porto Alegre; IDS,
orn errors of metabolism; kDa, kilodaltons; LC, liquid chromatografy; MS, mass spectrometry; LREIM-HCPA, Laboratório
e Porto Alegre; LSD, lysosomal storage disease; MgCl2, magnesium chloride; ML II, mucolipidosis type II; ML III, mucolipidosis
P, mannose-6-phosphate; PCR, polymerase chain reaction; Pmol, picomol; PolyPhen, polymorphism phenotyping; PRONEX,
onucleic acid; SIFT, sorting intolerant from tolerant; taq DNA polymerase, thermostable DNA polymerase.
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Mucolipidosis type II alpha/beta (MLII; MIM#252500) and type III
alpha/beta (MLIII; MIM#252600) are inherited autosomal recessive
diseases caused by deﬁcient activity of UDP-N-acetylglucosamine: ly-
sosomal hydrolase N-acetyl-1-phosphotransferase (UDP-GlcNAc-
phosphotransferase, GlcNAc-PT or phosphotransferase; EC 2.7.8.17)
(Brooks et al., 2007; Tiede et al., 2005; Zarghooni and Dittakavi,
2009). Phosphotransferase plays a role in the synthesis of mannose-6-
phosphate (M6P), amarkermolecule responsible for directing lysosom-
al hydrolases to the lysosome (Braulke et al., 2008; Cathey et al., 2008;
Tiede et al., 2005). In the absence of M6P residues, correct targeting of
lysosomal hydrolases is impaired, which results in massive secretion
of these enzymes in both the extracellular space and body ﬂuids, as
well as a decrease of their activity in cells such as ﬁbroblasts (Braulke
et al., 2008; Cathey et al., 2008; Encarnação et al., 2009). MLII is the
most severe form of the disease, and is often apparent at birth; progres-
sion is rapid, leading to death as early as the ﬁrst decade of life due to
cardiorespiratory complications. Conversely, MLIII follows a slower
clinical course, and patients have been known to survive until the
eighth decade of life (Cathey et al., 2010; Encarnação et al., 2009;
Kornfeld and Sly, 2001). MLII and III correspond to the extreme pheno-
types associatedwith phosphotransferase, deﬁciency, and patientswith
intermediate clinical manifestations have also been described (Cathey
et al., 2010).
Phosphotransferase is a hexameric protein composed of two α
subunits, two β subunits, and two γ subunits (Bao et al., 1996;
Tiede et al., 2005), where the α and β subunits are encoded by the
GNPTAB gene, located in chromosome 12q23.3, and the γ subunits
encoded by the GNPTG gene, located in chromosome 16p13.3
(Cathey et al., 2008; Encarnação et al., 2009; Kudo et al., 2005;
Zarghooni and Dittakavi, 2009). Patients who are homozygous or
compound heterozygous for pathogenic mutations in GNPTAB (ML
alpha/beta) exhibit a phenotype consistent with MLII or MLIII, where-
as patients who are homozygous or heterozygous for pathogenic mu-
tations in GNPTG (ML gamma) exhibit a phenotype compatible with
MLIII (Bargal et al., 2006; Cathey et al., 2010; Encarnação et al.,
2009; Persichetti et al., 2009; Tappino et al., 2009).
Themain objective of the present study was to conduct an analysis
of the GNPTAB gene in Brazilian patients with MLII and III alpha/beta.
2. Materials and methods
Twelve unrelated patients with a biochemical diagnosis of MLII or
MLIII were included in the study. They were recruited from the cohortc.242G>T c.1208T>C
c.1196 C>T
c.1514 G>A
c.1123C>T
c.17
1 2 3 4 5 6 7 8 9 10 11 12 1
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Fig. 1. GNPTAB gene: localization of pathogenic mutations found in the present study (mod
present study. In black: mutations previously described in the literature. The α- and β-subof patients (approximately 40,000) investigated for inborn errors of me-
tabolism (IEM) at the Reference Laboratory for IEM at Hospital de
Clínicas de Porto Alegre, Brazil (LREIM-HCPA), from 1983 to 2011. The
LREIM-HCPA is a national reference laboratory for the diagnosis of lyso-
somal diseases, and its database of diagnoses probably includes most
cases of MLII/III diagnosed in Brazil. Biochemical diagnosis of MLII/III at
LREIM-HCPA includes analysis of arylsulfatase A (ARSA; EC 3.1.6.8) and
several other lysosomal hydrolases, including α-L-iduronidase (IDUA;
EC 3.2.1.76), iduronate-sulfatase (IDS; EC 3.1.6.12), β-glucuronidase
(GUSB; EC 3.2.1.31), and β-hexosaminidase (EC 3.2.1.30), in plasma.
Measurement of the activity of these enzymes in ﬁbroblasts, as well as
analysis of glycosaminoglycans (GAGs) and sialyloligosaccharides in
urine, are also performed whenever samples are available. If only ﬁlter
paper samples are available, the activity of IDS, GUSB, and hexosamini-
dases is analyzed.
Whole blood samples were collected for gDNA and RNA extrac-
tion. Determination of clinical severity (ML II or III) took into account
the criteria usually reported in the literature, such as age at diagno-
sis, survival, and extent of skeletal involvement (and, consequently,
patient height) (Cathey et al., 2010). The patients included in this
study were under the care of different physicians, but a summary
of their clinical records was always sent alongside each patient's
blood sample, so that the classiﬁcation assigned by the attending
physician was always reviewed and conﬁrmed by the investigators.
Whenever possible, a sample of gDNA from the parents was also
obtained for conﬁrmation of the presence of the mutations found in
the patient.
Genomic DNA was extracted from peripheral blood leukocytes
with the DNeasy Blood and Tissue Kit (Qiagen, Germany). The 21
exons that comprise the GNPTAB gene, as well as the intron-exon
boundaries and part of the 5′ and 3′ untranslated regions, were am-
pliﬁed from the speciﬁc sequences of oligonucleotides projected for
this study. Ampliﬁcation was performed by the polymerase chain re-
action (PCR) using 50 ng of gDNA, 16 pmol of each oligonucleotide,
0.6 mM of dNTPs, 2.4 mM of MgCl2, 1× reaction buffer, and 1 unit
of taq DNA polymerase. The annealing temperatures and oligonucleo-
tide sequences are available as supplementary data.
Sample sequencing was performed using the automatic ABI-PRISM
3100 Genetic Analyzer (Applied Biosystems). The reference sequence
of the GNPTAB gene was GenBank accession nº. NM_024312.3. Each
mutation found was conﬁrmed by sequencing performed with a
new amplicon and the oligonucleotide inverse to that used in the
ﬁrst stage.
In silico analysis of the potential effect of missense mutations
was done by means of PolyPhen2 (Polymorphism Phenotyping)c.2808A>G
c.2269_2273delGAAAC
c.3503_3504delTC
59C>T
3 14 15 16 17 18 19 20 21
β
iﬁed from Tappino et al. (2009)). In red: mutations described for the ﬁrst time in the
units are represented.
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61G.K. Cury et al. / Gene 524 (2013) 59–64(http://genetics.bwh.harvard.edu.pph2/) and SIFT (Sorting Intoler-
ant From Tolerant) (http://sift.jcvi.org/www.SIFT_seq_submit2.html).
The MaxEntScan software was used to evaluate the effect of point mu-
tations on generation or exclusion of splice sites (http://http://
genes.mit.edu/burgellab/maxent/Xmaxentscan_scoreseq.html). The
frequency of synonymous codon usage was evaluated according to the
database of codon usage in Homo sapiens (http://www.kasuza.or.jp/
codon/cgi-bin/showcodon.cgi?species=9606). To evaluate the pathoge-
nicity of the novel exonic point mutation found (c.2808A>C), a hundred
control alleles were analyzed using 0.3 U of Hyp 188I restriction enzyme
(New England Biolabs, USA), 2 μl of buffer 4 (supplied with the restric-
tion enzyme) and 17.7 μl of amplicon; samples were incubated for 3 h
at 37 °C. Total RNA extraction was performed on a whole blood sample
from the patient presenting this mutation using the Paxgene blood
RNA Kit (Qiagen, Germany), and conversion to cDNA was made using
the Superscript II conversion kit (Invitrogen, USA), according tomanufac-
turer instructions. cDNA was subsequently sequenced as described
above.
This study was approved by the Hospital de Clínicas de Porto
Alegre (HCPA) Research Ethics Committee.nr
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d.3. Results
Of the patients included, eight were classiﬁed as having MLII.
Only one (patient 12) was born of consanguineous parents. Regard-
ing biochemical investigation, ﬁbroblast samples were unavailable
for three patients (patients 6, 7 and 12); patient 6 was investigated
only through a dried blood spot (DBS) sample. Urinary GAG mea-
surements were normal in 10 of 10 patients, thin-layer chromatogra-
phy of GAGs was abnormal in 4 of 10 patients (patient 4, dermatan/
keratan sulfate; patients 5 and 7, dermatan sulfate; patient 9, keratan
sulfate), while thin-layer chromatography of sialyloligosaccharides
was abnormal in 1 of 3 patients (patient 10). Detailed data on the
clinical and biochemical ﬁndings presented by the patients are avail-
able as supplementary material.
Nine causal sequence variations were found, two of which were
novel: c.2808A>G (p.Y937_M972del) and c. 2269_2273delGAAAC
(p.E757KfsX2) respectively (Fig. 1, Table 1). Both pathogenic mutations
were identiﬁed in 8 of 12 patients, and only one pathogenic mutation
was identiﬁed in four patients (Table 1). Mutation c.3503_3504delTC,
located in exon 19, was the most frequent pathogenic mutation (n =
11/24 alleles; Table 1).
At least one nonpathogenic variant was found in each patient.
The mutations c.365+145C>T in intron 4 (n = 17/24) and
c.-41_-39delGGC in the 5′UTR (n = 16/24) were the most frequent
nonpathogenic variants found, and the nonpathogenic mutation
c.323+20delT (intron 3) has not been reported elsewhere. Addi-
tional information on nonpathogenic mutations is available as sup-
plementary material.Ta
bl
e
1
Pa
th
og
en
ic
m
ut
at
io
ns
fo
un
d
in
th
e
G
N
PT
A
B
ge
ne
of
12
u
Pa
ti
en
ts
G
en
ot
yp
e
(c
D
N
A
)
1
c.
[1
12
3C
>
T]
+
[?
]
2
c.
[1
51
4G
>
A
]+
[1
75
9C
>
T]
3
c.
[1
20
8T
>
C]
+
[3
50
3_
35
04
de
lT
C]
4
c.
[3
50
3_
35
04
de
lT
C]
+
[?
]
5
c.
[2
42
G
>
T]
+
[?
]
6
c.
[2
26
9_
22
73
de
lG
A
A
A
C]
+
[2
26
9_
22
73
de
lG
A
7
c.
[2
80
8A
>
G
]+
[3
50
3_
35
04
de
lT
C]
8
c.
[1
19
6C
>
T]
+
[3
50
3_
35
04
de
lT
C]
9
c.
[3
50
3_
35
04
de
lT
C]
+
[?
]
10
c.
[3
50
3_
35
04
de
lT
C]
+
[3
50
3_
35
04
de
lT
C]
11
c.
[3
50
3_
35
04
de
lT
C]
+
[3
50
3_
35
04
de
lT
C]
12
c.
[3
50
3_
35
04
de
lT
C]
+
[3
50
3_
35
04
de
lT
C]
?:
U
ni
de
nt
iﬁ
ed
m
ut
at
io
n;
N
A
:n
ot
an
al
yz
ed
;N
I:
no
in
te
r
ab
le
at
ht
tp
:/
/s
ift
.jc
vi
.o
rg
/w
w
w
/S
IF
T_
se
q_
su
bm
it
2.
ht
m
a
⁎
Co
nd
uc
te
d
on
ly
in
ca
se
of
m
is
se
ns
e
m
ut
at
io
ns
.
⁎
⁎
Pa
re
nt
s
w
er
e
an
al
yz
ed
on
ly
in
re
la
ti
on
to
th
e
m
ut
at3.1. The c.2808A>G mutation
As the c.2808A>Gmutation (exon 14)was apparently not associated
with an amino acid change, we decided to investigate its effect on splic-
ing. According to MaxEntScan software (http://http://genes.mit.edu/
burgellab/maxent/Xmaxentscan_scoreseq.html) results, this mutation
would strongly interfere with GNPTAB mRNA splicing (Fig. 2). In fact,
this mutation creates a similar sequence to the canonical donor splice
site. cDNA analysis for this patient showed the presence of an abnormal
transcript in which the ﬁnal 108 bp of exon 14 is absent (Fig. 3). We
did not perform expression studies, but this isoform is predicted to gen-
erate a truncated protein (p.Y937_M972del), with deletion of 36 amino
acids of the phosphotransferase β-subunit. This mutation was not
found in any of the 100 control alleles analyzed (Fig. 4).
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This is the ﬁrst study to describe the pathogenic/nonpathogenic
mutation spectrum of the GNPTAB gene in Brazilian patients with
MLII and III alpha/beta. As in other populations, this analysis con-
ﬁrmed that GNPTAB exhibits great allelic heterogeneity, that there
are few recurrent mutations, and that c.3503_3504delTC is the most
prevalent pathogenic mutation (Bargal et al., 2006; Cathey et al.,
2010; Kudo et al., 2006; Paik et al., 2005; Tiede et al., 2005). Further-
more, three novel sequence variations (two pathogenic) are de-
scribed herein.
The number of patients included in this study (n = 12) is signiﬁ-
cant, considering that all patients were Brazilian and that ML is quite
rare and severe (http://www.geneclinics.org). Unfortunately, not all
patients had undergone biochemical investigation in plasma and/or
ﬁbroblasts. It bears stressing, however, that all patients exhibited a
clinical phenotype consistent with MLII or MLIII. Patient 6 was inves-
tigated using ﬁlter paper only, as described by Chamoles et al. (2001);
as this patient was later conﬁrmed as having ML II alpha/beta through
DNA analysis, this ﬁnding corroborates the hypothesis that DBS sam-
ples can also be used for MLII/III screening. Interestingly, four patients
exhibited an abnormal pattern on urinary thin-layer chromatography
of GAGs, although their levels of total urinary GAGs were normal. Ab-
normal catabolism of GAGs is expected to occur in patients with MLII/
III, as lysosomal enzymes involved in the catabolism of GAGs are de-
ﬁcient in these disorders. Levels of keratan sulfate (determined by
ELISA), as well as dermatan sulfate and heparan sulfate (determined
by LC/MS/MS), were found to be increased in plasma of some patients
with MLII/II (Tomatsu et al., 2005, 2010). However, secretion of ab-
normal GAGs is usually too low in MLII/III patients to be detected by
thin-layer chromatography.
The methodology used in the present study was able to identify 20
of 24 pathogenic alleles (roughly 83%). This rate is not very different
from that reported in the literature (approximately 95%) (http://
www.geneclinics.org). The most frequently found pathogenic muta-
tion was c.3503_3504delTC, which was present in homozygosity in
three MLII patients (patients 10, 11 and 12) and in heterozygosity
in another two MLII patients (patients 4 and 7) and three MLIII pa-
tients (patients 3, 8 and 9); the prevalence found for this mutation
in our study (45%; 11 of 24 alleles) is similar to that described in
the literature. Bargal et al. (2006) found this same mutation in 13 of
24 MLII patients, most of Arab-Muslim origin (11 homozygous; 2
compound heterozygous; 10 born to consanguineous couples).
Encarnação et al. (2009) found this microdeletion in ﬁve patients
with MLII (n = 9 of 18 alleles); four of these patients were homozy-
gous for the mutation. Tappino et al. (2009) identiﬁed this mutationgt ag
gt ag
EExon 13
EExon 13
A
B
Fig. 2. Schematic representation of exons and introns 13, 14 and 15 of the GNPTAB gene an
obtained in the presence of c.2808A>G. Dotted line: new splicing. X: splicing replaced.in 47 of 92 alleles; it was found in homozygosity in 14 patients with
MLII, most of whom were Italian and born to non-consanguineous
couples. Mutation c.3503_3504delTC was the only pathogenic muta-
tion identiﬁed in the sample studied by Plante et al. (2008).
4.1. Effect on phenotype
Our data suggest that nonsense and frameshiftmutations are associ-
ated with the severe phenotype (MLII alpha/beta), whereas missense
mutations are associated with the attenuated phenotype (MLIII alpha/
beta). These ﬁndings are in agreement with those previously described
in the literature (Bargal et al., 2006; Encarnação et al., 2009; Tiede et al.,
2005).
Thus far, c.3503_3504delTC, located at the region that codes for the
β subunit of phosphotransferase, has been associated with the severe
phenotype when found in homozygosity or when found in heterozy-
gosity with nonsense mutations or frameshift mutations. Three of our
patients with MLII alpha/beta presented this deletion in homozygosity
(patients 10, 11 and 12). However, two patients with MLIII alpha/beta
(patients 3 and 8, respectively) presented this deletion in heterozygos-
ity with the missense mutations c.1208T>C (p.I403T) and c.1196C>T
(p.S399F), both located at the region that codes for the α subunit of
phosphotransferase. Other authors have also reported cases of com-
pound heterozygosity for mutations in the α and β subunits (Cathey
et al., 2010; Tappino et al., 2009), and Bargal et al. (2006) suggest that
there is no intragenic complementation between these subunits. The
genotype c.[1196C>T]+[3503_3504delTC] (patient 8)was also reported
in a MLIII French patient by Bargal et al. (2006). In that same study, the
authors reported that this patient exhibited a severe MLIII phenotype
and that ﬁbroblast testing showed cytoplasmic inclusions typical of pa-
tients with MLII. Our patient may also be considered a patient with se-
vere MLIII alpha/beta, given the severity of his skeletal compromise,
which is reﬂected by his present height. The c.[1208T>C]+[3503_
3504delTC] genotype, on the other hand, is being described for the ﬁrst
time herein (patient 3, MLIII alpha/beta). Mutation c.1208T>C
(p.I403T) has already been described by Tappino et al. (2009) in homo-
zygosity in an Italian patient with MLIII, as well as by Encarnação et al.
(2009) in a Portuguese patient. Expression studies of the mutant
p.I403T protein in COS cells conducted by Tappino et al. (2009) showed
that this mutation had an expected molecular mass of 170 kDa, and the
authors presumed that the resulting protein would be partially dysfunc-
tional, which could explain the attenuated phenotype exhibited by these
patients.
Genotype c.[1514G>A]+[1759C>T] was found in one patient
with MLIII alpha/beta (patient 2). The ﬁrst is a missense mutation
(p.C505Y), while the second is a nonsense mutation (p.R587X). Thisgt ag
2.29 
5’ss
gt ag
9.8
5’ss
X
Exon 15xon 14
Correct splice
product
Mutant
transcript
Exon 15xon 14
MaxEnt Scan
score
MaxEntScan
score
d scores obtained with the MaxEntScan program for wild (A) and mutated (B) forms
Fig. 3. Electrophoresis of RT-PCR for the c.2808A>G mutation (patient 7) showing the
normal transcript (A) and the alternative transcript (B). 1: Standard molecular weight;
2: negative control for c.2808A>G; 3: patient sample.
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have already been reported by Cathey et al. (2010), in compound het-
erozygosity, in a patient with MLII (p.R587X) and in one patient with
MLIII (p.C505Y).
Genotype c.[242G>T]+[?] was found in a patient with ML II
alpha/beta (patient 5). Encarnação et al. (2009) described this muta-
tion, in homozygosity, in one of their Portuguese patients with MLIII.
One hypothesis that might justify the phenotype of patient 5, with
only one pathogenic mutation identiﬁed, would be the presence of
two silent mutations in exon 1 of the second allele: c.18G>A and
c.27G>A. The ﬁrst induces a change from the sixth CUG codon (fre-
quency of codon usage per thousand = 39.6) to CUA (frequency of
codon usage per thousand = 7.2). The second mutation changes theExon 14
A
B
Fig. 4. A) Patient 7 (genotype: c.2808A>G; p.Y937_M972del): Sequencing of the abnormal
part of exon 13; in black, exon 14; in green, exon 15; in orange, exon 16; underlined, mutaninth CAG codon (frequency of codon usage per thousand = 34.2)
to CAA (frequency of codon usage per thousand = 12.3) (http://
www.kasuza.or.jp/codon/cgi-bin/showcodon.cgi?species=9606).
This could cause a greater change in the translation kinetics of the
protein, generating a protein with an altered conformation (Komar,
2007; Sauna and Kimchi-Sarfaty, 2011). Unfortunately, parental
DNA and patient ﬁbroblasts were unavailable, and, therefore, we are
not able to conﬁrm whether these mutations are in cis or in trans. Ad-
ditional studies will be conducted to conﬁrm this hypothesis.5. Conclusions
Thiswas the ﬁrst DNA analysis-based study conducted in Brazilian pa-
tients with ML alpha/beta. Its ﬁndings suggest that analysis of GNPTAB in
these patients should begin by exon 19, thus optimizing the investigation
and reducing costs. The results obtained herein emphasize the need for
further studies, such as application of other techniques that will enable
completion of genotyping of the patients whose genotype has not been
fully characterized (e.g. sequencing of promoter and intronic regions, ex-
clusion of large deletions/rearrangements), and for determination of the
frequency of recurrent variants in healthy Brazilian individuals.Acknowledgments
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